Incidence of cytopenias by azole subgroup in patients with GVHD. Patients with SR-aGVHD (A) and patients with SR-cGVHD (B) treated with ruxolitinib (RUX) or BAT, with or without azoles. Data reported for safety analysis set. ANC, absolute neutrophil count; WBC, white blood cell.